Purpose: To assess metamorphopsia in patients with macular telangiectasia (MacTel) type 2.
Methods: In a prospective observational cohort study, 40 eyes of 20 patients with MacTel type 2 were investigated by funduscopy, fluorescein angiography, optical coherence tomography and microperimetry. Metamorphopsia was assessed using Amsler grids following a standard protocol and standardized questionnaire.
Results: Metamorphopsia was present in 30 (83%) out of 36 nonproliferative eyes and in all four eyes with neovascular membranes. In the 30 nonproliferative eyes with distortions, metamorphopsia was always present in the nasal quadrant of the central visual field. Distortions were most pronounced in the nasal and lower quadrant in 70 and 30%, respectively. Three nonproliferative eyes with a very early and three eyes with a late disease stage did not perceive metamorphopsia. The degree of distortions was often but not necessarily correlated with the degree of leakage. Metamorphopsia was present in five out of eight eyes with normal sensitivity in microperimetry testing. Detection of scotoma by Amsler grid testing was poor.
Conclusion: Metamorphopsia is a frequent clinical symptom in MacTel type 2 even in the absence of neovascularization. Since macular thickness was within normal limits in such eyes, extensive swelling or distortion of the neurosensory retina would not account for metamorphopsia in contrast to other macular diseases such as age-related macular degeneration or idiopathic epiretinal membranes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10633-009-9190-9 | DOI Listing |
Retin Cases Brief Rep
December 2024
Department of VitreoRetina, Aditya Birla SankaraNethralaya,147, Mukundapur, E.M. Bypass, Kolkata-700 099, West Bengal, India.
Purpose: To report OCTA (Optical coherence tomography angiography) characteristics of bilateral MacTel type 1 with capillary obliteration.
Method: Colour fundus photo (CFP), OCT angiography (OCTA), Fundus fluorescein angiography (FFA), Fundus autofluorescence (FAF).
Result: We describe three cases of bilateral MacTel Type 1 with a special emphasis on OCTA characteristics.
Invest Ophthalmol Vis Sci
December 2024
Department of Ophthalmology, University of Bonn, Bonn, Germany.
Purpose: The relative ellipsoid zone reflectivity (rEZR) is an innovative biomarker for photoreceptor alterations and showed association with disease staging in macular telangiectasia type 2 (MacTel). However, its prognostic relevance for the ellipsoid zone (EZ) loss is unclear.
Methods: Longitudinal spectral-domain optical coherence tomography (SD-OCT) imaging of patients with MacTel from an observational natural history study was used for en face determination of manifest EZ loss.
Ophthalmol Sci
September 2024
Oculogenetic Unit, Jules Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland.
Angiogenesis
November 2024
The Lowy Medical Research Institute, La Jolla, CA, USA.
In multiple neurodegenerative diseases, including age-related macular degeneration, retinitis pigmentosa, and macular telangiectasia type 2 (MacTel), retinal pigment epithelial (RPE)-cells proliferate and migrate into the neuroretina, forming intraretinal pigment plaques. Though these pigmentary changes are hallmarks of disease progression, it is unknown if their presence is protective or detrimental.Here, we first evaluated the impact of pigment plaques on vascular changes and disease progression in MacTel.
View Article and Find Full Text PDFEur J Ophthalmol
November 2024
Ophthalmology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Purpose: To describe the successful use of plasma rich in growth factors (PRGF-Endoret®) and internal limiting membrane peeling for full thickness macular hole in Macular Telangiectasia type 2.
Case Presentation: A case report of a full thickness macular hole (FTMH) associated with Macular Telangiectasia (MacTel) type 2 is described. 25-G vitrectomy with internal limiting membrane (ILM) peeling and use of (PRGF-Endoret®) was performed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!